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Abstract
Background: Sympathetic nervous system (SNS) signalling regulates murine hepatic fibrogenesis through effects on hepatic
stellate cells (HSC), and obesity-related hypertension with SNS activation accelerates progression of non-alcoholic fatty liver
disease (NAFLD), the commonest cause of chronic liver disease. NAFLD may lead to cirrhosis. The effects of the SNS
neurotransmitters norepinephrine (NE), epinephrine (EPI) and neuropeptide Y (NPY) on human primary HSC (hHSC) function
and in NAFLD pathogenesis are poorly understood.
Aims: to determine the mechanistic effects of NE/EPI/NPY on phenotypic changes in cultured hHSC, and to study SNS
signalling in human NAFLD livers.
Methods: Freshly isolated hHSC were assessed for expression of cathecholamine/neuropeptide Y receptors and for the
synthesis of NE/EPI. The effects of NE/EPI/NPY and adrenoceptor antagonists prazosin (PRZ)/propranolol (PRL) on hHSC
fibrogenic functions and the involved kinases and interleukin pathways were examined. Human livers with proven NAFLD
were then assessed for upregulation of SNS signalling components.
Results: Activated hHSC express functional a/b-adrenoceptors and NPY receptors, which are upregulated in the livers of
patients with cirrhotic NAFLD. hHSC in culture synthesize and release NE/EPI, required for their optimal basal growth and
survival. Exogenous NE/EPI and NPY dose-dependently induced hHSC proliferation, mediated via p38 MAP, PI3K and MEK
signalling. NE and EPI but not NPY increased expression of collagen-1a2 via TGF-b without involvement of the pro-
fibrogenic cytokines leptin, IL-4 and IL-13 or the anti-fibrotic cytokine IL-10.
Conclusions: hHSC synthesize and require cathecholamines for optimal survival and fibrogenic functionality. Activated
hHSC express directly fibrogenic a/b-adrenoceptors and NPY receptors, upregulated in human cirrhotic NAFLD.
Adrenoceptor and NPY antagonists may be novel anti-fibrotic agents in human NAFLD.
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Introduction
The sympathetic nervous system (SNS), a major branch of the
autonomic nervous system, is responsible for up- and down-
regulating many homeostatic mechanisms in living organisms. Pre-
and post-ganglionic neurons are involved in the transmission of
signals through the sympathetic system. At the synapses within the
ganglia, preganglionic neurons release acetylcholine, a neuro-
transmitter that activates nicotinic acetylcholine receptors on
postganglionic neurons. In response to this stimulus postganglionic
neurons release catecholamines such as norepinephrine, which
activate adrenergic receptors on the target tissues. The activation
of target tissue receptors causes the effects associated with the
sympathetic system such as vasoconstriction and hypertension.
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Hepatic stellate cells (HSC), also known as peri-sinusoidal cells or
Ito cells, are pericytes found in the peri-sinusoidal space between
the sinusoids and hepatocytes in the liver. HSC are the principal
hepatic fibrogenic cells generating scar tissue in response to
persisting liver injury [1]. Emerging evidence suggests that HSC
express functional adrenoceptors [2,3], and SNS neurotransmit-
ters induce in vitro HSC characteristic pro-fibrotic phenotypic
changes [4,5]. Additionally, mice with genetic deletion of
dopamine-b-hydroxylase, lacking cathecholamines, are poorly
fibrogenic [2]. Neuropeptide Y (NPY), co-released with cathe-
cholamines at SNS nerve terminals modulates in turn cathecho-
lamine release [6,7] and induces murine HSC proliferation but not
collagen expression [5]. The applicability of these findings to
human liver fibrosis is unknown. Nearly 4 decades ago it was
envisaged that SNS activation is an adaptive response to
overeating helping to stabilise body weight [8] with underfed
rodents suppressing their SNS activity. Similar effects observed in
humans provide support for a key role for the SNS in obesity.
Overfeeding concurrently stimulates cardiac sympathetic nerves,
which are proposed to be a reflex response to circulatory overload
[9,10]. Hypertension observed with SNS activation is a compo-
nent of the metabolic syndrome and obesity [9–11]. In 90% of
cases obesity is associated with non-alcoholic fatty liver disease
(NAFLD), an accumulation of intra-hepatic triglycerides that is
often considered the hepatic manifestation of insulin resistance.
NAFLD is the most common cause of chronic liver disease in
Western countries with up to one third of the US population
affected [12]. NAFLD is a spectrum of hepatic disorders that
encompass varying degrees of liver damage ranging from steatosis
to non-alcoholic steatohepatitis (NASH) characterized by hepato-
cellular injury and fibrosis which may progress to cirrhosis and
hepatocellular carcinoma [13–15]. There is currently no pharma-
cological treatment for NAFLD, other than loss weight and
physical exercise [16]. The aim of this study was to determine if
human HSC (hHSC) synthesize and respond to cathecholamines
or NPY, and explore the signalling pathways therein involved.
Moreover, we have studied changes in SNS signalling components
in liver specimens from NAFLD patients.
Materials and Methods
Isolation and culture of hHSCs
Human HSCs were isolated as described [17] from resected
normal liver tissue, in patients undergoing clinically indicated
resection of liver metastases. These liver specimens were obtained
with appropriate local Ethics Committee approval (UCL – Royal
Free Hospital, London, UK). Written informed consent from the
donors was obtained for use of samples in research. Experiments
were performed with hHSCs in culture at 7–30 days. Proliferation
experiments were performed at first hHSC activation [5,18] and
not on multiply passaged cells. A subset of experiments was
performed with freshly isolated, quiescent HSCs.
Near normal and cirrhotic non-alcoholic steatohepatitis
liver specimens
With appropriate ethical approval and consent for research,
liver specimens were obtained from adult patients undergoing
clinically indicated investigations for NAFLD or liver transplan-
tation in our units. A total of 10 human liver specimens were used
in the current study: 5 were from liver biopsies in patients in whom
the final diagnosis was near normal liver – Brunt-Kleiner [19]
NAFLD liver fibrosis score = F0; and 5 were from peri-transplant
resected specimens in whom the final diagnosis was cirrhotic
NAFLD, BK NAFLD fibrosis score =F4. The histopathological
evaluations were performed by an expert liver histopathologist.
Table 1. RT-PCR primers used to amplify adrenoceptors transcripts.
Gene Primer sequences (5939) Annealing (6C) Product size (bp)
Collagen 1a2 Sense: GAA CGG TCC ACG ATT GCA TG
Antisense: GGC ATG TTG CTA GGC ACG AAG
55 167
TGF-b1 Sense: CTA CTA CGC CAA GGA GGT CAC
Antisense: TTG CTG AGG TAT CGC CAG GAA
55 246
a1A Sense: TGG CCG ACC TCC TGC TCA CCT C
Antisense: GGC CCC GGC TCT CCC TCT TG
55 444
a1B Sense: CCC CCG ACG CCG TGT TCA AGG TG
Antisense: CTC AGG CGC GGG CAG GCT CAG GA
55 407
a1D Sense: AGC GCT TCT GCG GTA TCA
Antisense: GGA GGA AGG CGC GCT TGA AC
55 516
b1 Sense: GTG GCC CTG CGC GAG CAG AA
Antisense: GCG GCA GTA GAT GAT GGG GTT GA
55 195
b2 Sense: TCA TCA CTT CAC TGG CCT GT
Antisense: CTT GGT CAG CAG GCT CTG GT
55 230
b3 Sense: GTC GTT TGC GCC CAT CAT GA
Antisense: AGC AGA GAG TGA AGG TGC CC
55 410
IL-4 Sense: GAA GAG AGG TGC TGA TTG GC
Antisense: GGT TCC TGT CGA GCC GTT TC
53 530
IL-10 Sense: CAT CAA GGC GCA TGT GAA CT
anti-sense: CTT GGA ATG GAA GCT TCT GT
53 590
IL-13 Sense: GAG ACA GGA CCT GAC TAT TG
anti-sense: AGA ATT CTG TAC ACA GTA CT
53 540
GAPDH Sense: AGT ATG ACT CCA CTC ACG GCA A
Antisense: TCT CGC TCC TGG AAG ATG GT
55 100
doi:10.1371/journal.pone.0072928.t001
Sympathetic Nervous System as a Target for NAFLD
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e72928
Immunocytochemistry and confirmation of hHSC identity
hHSC were prepared and stained for alpha smooth muscle actin
(ASMA) and glial fibrillary acidic protein (GFAP) with controls as
described [5,18]. Images were captured with a Zeiss Axiophot
microscope and a Leica DMRE fluorescence microscope fitted
with an SP confocal head.
High performance liquid chromatography (HPLC)
analysis
Cathecholamines were extracted from HSC conditioned
medium as described [2] and an aliquot was injected into a
reverse phase ion pair HPLC system with electrochemical
detection using ESA Coulochem5100 A.
Cell proliferation assay
Quantitative hHSC proliferation assays were performed with
the WST-8 cell counting kit (Dojindo Molecular Technologies,
NBS Biologicals, Huntingdon, Cambridgeshire, UK) as described
[5,18].
Apoptosis assay
hHSC (56105/ ml) were plated into 6 mm petri dishes with test
agents. Cells without serum served as positive control of apoptosis
and cells cultured with PDGF served as a negative control of
apoptosis. At harvest, 48 hours later, apoptotic activity was
assessed with the Vybrant (annexin V) apoptosis assay kit 2
(Molecular Probes, Invitrogen). FACS analysis was performed
using a Becton-Coultor flow cytometer.
RT-PCR
RT-PCR was performed as previously described [20]. RNA was
isolated from activated hHSCs using TRizol (Invitrogen) and
cDNA synthesized using QuantiTect Rev. Transcription kit
(Invitrogen). Quantitative RtPCR was performed using a Rotor-
gene RG-3000 instrument (Corbett Research), SYBR GreenER
and a 2 Step qRT-PCR kit (Invitrogen). Target gene levels in
treated samples are presented as a ratio to levels detected in
corresponding control samples, according to the DDCt method.
For semi-quantitative PCR, Superscript III one-step RT-PCR
with platinum Taq kit (Invitrogen) and classic II 18s internal
standard kit (Ambion) was used. The cycle number and 18 S
primer/ competimer pair ratio for each primer set were
determined by the manufacture’s instruction. PCR products were
separated by electrophoresis and quantified by densitometry using
Figure 1. Characteristics of cultured hHSC: hHSC express GFAP
plus ASMA and basal proliferative activity of hHSC is maximal
at after 15 days in culture and reduces thereafter. a) Freshly
isolated cells hHSC in culture were confirmed as HSC by auto-
fluorescence, and expression of ASMA and GFAP verified at day 4, by
immunocytochemistry. b) Basal proliferative activity of hHSC was
maximal at day 15 (non-passaged, not fully activated), compared to day
7 (non-passaged, not fully-activated) or day 30 (passaged, fully-
activated) with basal proliferative activity less at day 30 compared to
day 15. *p,0.05, **p,0.0001, n = 5, compared to control response.
doi:10.1371/journal.pone.0072928.g001
Table 2. RT-PCR primers used to amplify neuropeptide Y receptors (NPY) transcripts.
Gene Primer sequences (5939) Annealing (6C) Product size (bp)
NPY1R Sense: GAAAATCATTCAGTCCACTC
Antisense: GGATGTTGGTAACATTTCTC
55 205
NPY2R Sense: GAGTATTCGCTGATTGAGAT
Antisense: GGTTCTTCAATTTACTCCAA
55 184
NPY4R Sense: CTTCCTACAGCATTGAGACT
Antisense: AAAGATCCAGTAGTCCATGA
55 191
NPY5R Sense: ACTACGGTAAACTTCCTCA
Antisense: TGACACACATTGAAGAAAAG
55 154
NPY6R Sense: CCACATGTATAAACCCTCTC
Antisense: GTTGTTATACGAGCCAATCT
55 175
GAPDH Sense: AGT ATG ACT CCA CTC ACG GCA A
Antisense: TCT CGC TCC TGG AAG ATG GT
55 100
doi:10.1371/journal.pone.0072928.t002
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LabWorks 4.6 software (UVP, USA). Primer sequences, annealing
temperatures and products sizes are as shown in Tables 1 and 2.
Western blotting
Western blotting analyses were performed as previously
described [21]. Aliquots of hHSC were homogenized with Radio
Figure 2. Primary hHSC express adrenoceptors and NPY receptors, upregulated in NAFLD cirrhosis. a, b) Semi-quantitative Rt-PCR and
Western blot analyses showing that cultured activated hHSC express a1A, b1, b2 and b3 adrenoceptorsm but not absent a1B or a1D adrenoceptors
as confirmed by protein level expression. PCR reactions were carried out for 35 cycles. c) Immunohistochemistry for hHSC, showed significant
upregulation of a1A, b1, b2 and b3 in livers of patients with NASH cirrhosis patients compared to near normal controls. *p,0.05.
doi:10.1371/journal.pone.0072928.g002
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Immunoprecipitation Assay (RIPA) buffer (150 mM NaCl,
20 mM Tris-HCL, 1% sodium deoxycholate, 0.1% SDS, and
1% NP-40, Sigma, UK) containing protease inhibitors (Roche
Applied Science, UK). Samples (30 mg protein) were prepared
according to the manufacturer’s instructions and loaded onto
precast 10% bis-tris polyacrylamide gels (Invitrogen, UK).
Western-blotting was performed with NuPage Electrophoresis
System (Invitrogen, UK) and blots incubated with rabbit primary
anti-b1 and anti-b2 adrenergic receptor antibodies (16600 and
16400, respectively; Santa Cruz Biotechnology, USA), goat anti-
b3 adrenergic receptor antibody (16400; ProSci, USA), rabbit
anti-NPY1 receptor antibody (16500; Abcam, UK), goat anti-
NPY4 and anti-NPY6 receptor antibodies (16500, Santa Cruz
Biotechnology, USA), and rabbit anti-b-actin antibody (161000;
Cell Signaling Technology, UK). Horseradish peroxidase-conju-
gated secondary antibodies, goat anti-rabbit IgG (Santa Cruz
Biotechnology, USA) and bovine anti-goat IgG (Jackson Immu-
noResearch Laboratories, USA) were used to detect primary
antibodies. Signals were detected using ECL Western Blotting
Detection Reagents (GE Healthcare, UK). Equal loading (30 mg)
was verified by comparing expression levels of b-actin.
Immunohistochemistry
Immunohistochemistry staining was performed as previously
described [22,23]. Briefly, four-mm-thick frozen sections of human
liver were cut, dried overnight at room temperature, fixed in
acetone and washed in PBS. All sections were incubated,
30 minutes, room temperature with primary antibodies. Primary
antibodies (Table 3) were from Santa Cruz Biotech, Heidelberg,
Germany. For DBH, b1- b2 and b3-AR samples were incubated
Table 3. List of antibodies, and relative dilutions, utilized for
immunoblotting.
Antibody
SCBT
Catalogue
No Source
Primary
Antibody
Dilution
a1A-AR (C-19) SC-1477 Goat polyclonal 1:20
b1-AR (V-19) SC-568 Rabbit polyclonal 1:200
b2-AR (H-73) SC-9042 Rabbit polyclonal 1:100
b3-AR (C-20) SC-1472 Goat polyclonal 1:10
DbH (H-213) SC-15317 Rabbit polyclonal 1:100
doi:10.1371/journal.pone.0072928.t003
Figure 3. Expression of NPY receptors in hHSC. a, b) hHSC also express NPY receptors with abundant Y1, Y4, and Y6 NPY receptors at mRNA
and protein levels with little or absent expression of Y2 and Y5.
doi:10.1371/journal.pone.0072928.g003
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with an anti–rabbit peroxidase–conjugated EnVision antibody
(Dako) 30 minutes/room temperature. For a1A-AR, a1B-AR,
a1D-AR and b3-AR, we used a three-step immunoperoxidase
procedure: peroxidase labeled rabbit-anti goat IgG (Dako, Den-
mark) followed by peroxidase labeled swine anti-rabbit IgG
(Dako). The secondary and tertiary antibodies were diluted
(1650 and 16100 respectively) in PBS, pH 7.2 containing 10%
normal human serum. For negative controls the primary antibody
was omitted. Number of hHSC positive for protein expression of
a1A, b1, b2 and b3 adrenoceptors in livers of patients with NASH
compared to near normal controls were assessed as previously
described [24].
Induction of leptin, IL-4, IL-10, IL-13 gene expression and
induction of leptin or IL-13 protein expression by NE
hHSC were cultured under conditions identical to those used
above to detect NE effects on hHSC proliferation. After 48 hours,
RNA was extracted from the cells and analysed by Q-RT-PCR for
expression of leptin, IL4, 10 and 13. Additionally, NE conditioned
hHSC media was assayed by ELISA for leptin and IL-13 with a
methodology as supplied – R&D systems, Abingdon, UK.
Drugs
All from Sigma, unless stated otherwise.
Statistical analysis
Data expressed as mean (6SEM). Statistical analyses performed
using the Mann-Whitney test, significance accepted as p,0.05.
Results
Characteristics of cultured hHSC
Upon isolation, primary hHSC cell identity and activation was
confirmed by their expression of established indicators, ASMA
and GFAP, verified at day 4 by immunocytochemistry (Figure 1a).
We confirmed with quantitative RT-PCR that after 10 days in
culture these cells had increased expression of ASMA by about
600%, decreased GFAP expression by about 50% and increased
collagen gene expression by about 400% compared to freshly
isolated cells at day 0 (results not shown). We then studied the
basal proliferative activity of hHSC after 7, 15 or 30 days in
culture (Figure 1b). Basal hHSC proliferation was maximal at day
15, compared to day 7 or 30 (Figure 1b). Therefore, subsequent
proliferation experiments were performed with hHSCs at day 15.
Primary hHSC express adrenoceptors and NPY receptors
which are upregulated in NAFLD Cirrhosis
We previously showed that murine HSC express mediocre
amounts of a1A, but exuberant a1B, a1D, b1 and b2
adrenoceptor subtypes [2]. The presence of some adrenoceptor
subtypes was recently shown in both activated hHSC and human
whole liver [3]. Here, we found by semi-quantitative RT-PCR that
culture activated hHSC express a1A, but had no detectable
expression of a1B or a1D adrenoceptors (Figure 2a). We also
observed expression of b1 and b2 adrenoceptors (Figure 2a). To
confirm protein level expression of these receptors, and assay their
possible functional significance in vivo, we first performed Western
blot analysis on hHSC lysate, and then immunohistochemistry for
hHSC on clinical liver specimens, either with a nearly normal
histology – fibrosis score, F0, or having NAFLD cirrhosis – fibrosis
score, F4. Western blot analysis confirmed protein level expression
of the b-adrenoceptors (Figure 2b) and immunohistochemistry
similarly showed a significantly upregulated number of hHSC
positive for protein expression of a1A, b1, b2 and b3
adrenoceptors in livers of patients with NAFLD cirrhosis
compared to near normal controls (Figure 2c).
We have previously shown that NPY, a SNS neurotransmitter
co-released with NE [7], induces murine HSC proliferation. The
expression of NPY receptors by hHSC is not known. Here, we
found that hHSC robustly express Y1, Y4, and Y6 NPY receptors
with little or no expression of Y2 and Y5 (Figure 3a, b). To confirm
the functional relevance of these receptors, we now analysed liver
RNA extracted from liver biopsies in patients with near-normal
livers, fibrosis score F0 (n= 3 patients) or cirrhotic NAFLD with
fibrosis score = F4 (n= 4 patients). As shown in Figure 4a and b,
patients with F0 fibrosis had little expression of Y1, Y4 or Y6 NPY
receptors whereas patients with F4 fibrosis (cirrhosis) had
exuberant expression of Y1, Y4 and Y6 NPY receptors indicating
that some NPY receptors as with adrenoceptors may be implicated
in the pathogenesis of NAFLD fibrosis since these receptors are
upregulated with fibrosis stage.
Primary hHSC express the cathecholamine synthesising
enzyme dopamine-b-hydroxylase and synthesize/release
NE plus EPI to regulate hHSC basal growth
Although murine HSC synthesize and release NE in culture and
use this endogenously released NE for optimal basal growth [2],
the existence of a similar pathway in hHSC is not known. We
Figure 4. Primary hHSC expressed NPY receptors are upregu-
lated in NAFLD. Semi-quantitative RT-PCR analysis, each lane
normalised against its corresponding GAPDH, of liver RNA from
patients with NASH fibrosis scored as F0 (n = 3 patients) or F4 (cirrhosis,
n = 4 patients) showing human livers with F0 fibrosis having little
expression of Y1, Y4 or Y6 NPY but exuberant expression of Y1, Y4 and
Y6 NPY in F4 fibrosis (cirrhosis); *p,0.001 compared to F0 control for
each receptor subtype, O.D. = optical density.
doi:10.1371/journal.pone.0072928.g004
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therefore examined by immunohistochemistry the expression of
DBH, the rate limiting enzyme in the biosynthesis of cathecho-
lamines. DBH was expressed by near normal livers and markedly
upregulated in livers with NASH cirrhosis compared to near
normal controls (mean counts of DBH positive cells 1761 vs. 262,
n = 5, p,0.001). HPLC analysis of hHSC conditioned medium
showed that hHSC release NE and EPI, with NE released at about
8369 pg/ml, more abundantly produced than EPI (Figure 5a). To
investigate the importance of endogenous NE and EPI and the
functionality of hHSC-expressed adrenoceptors, we cultured
hHSC with PRZ, a predominant a1-adrenoreceptor antagonist,
and PRL a predominant b-adrenoceptor antagonist. PRZ (10 mM)
and PRL (10 mM) singly or combined significantly reduced hHSC
basal growth (Figure 5b). Therefore, hHSC endogenously
produced cathecholamines are important for hHSC basal growth
via hHSC expressed adrenoceptors.
Exogenous NE, EPI and NPY stimulate proliferation of
hHSC through p38 MAP, PI3K and MEK
We then investigated whether exogenous NE and EPI as with
murine HSC [2] induced hHSC proliferation. Activated hHSC
were cultured for 48 hours in serum free medium, as negative
controls, or in medium with 10% FBS as controls or with 10%
FBS plus varying concentrations of NE (1 nM–1 mM). NE
induced a dose-dependent, biphasic, enhancement of proliferation
of hHSC with maximal effect at 10 nM (Figure 6a, b). EPI
similarly induced hHSC proliferation at 1 nM – 1 mM with
maximal effect at 10 nM (Figure 7a). The effect of EPI on hHSC
proliferation was mostly mediated by b-adrenoceptors, since PRL
significantly inhibited it (Figure 7b, top panel) whilst the effect of
NE on hHSC proliferation was mostly mediated by a-adrenocep-
tors, since PRZ significantly inhibited NE induced proliferation
(Figure 7b, bottom panel). NPY as with NE and EPI also induced
Figure 5. Primary hHSC express the cathecholamine synthesising enzyme dopamine-b-hydroxylase and synthesize/release NE plus
EPI to regulate hHSC basal growth in culture. a) We first established by immunohistochemistry that hHSC expressed dopamine-b-hydroxylase
(DBH) (data not shown). HPLC analysis of hHSC conditioned medium showed hHSC release of NE and EPI with NE more abundantly produced than
EPI. b) Activated hHSC cultured basally for 48hours with PRZ (10 mM) or PRL (10 mM) singly or in combination significantly had reduced basal
proliferation. Proliferation under each treatment condition was normalised to the corresponding serum free control in each experiment; *p,0.05,
**p,0.0001, each bar represents mean 6SEM, n = 3.
doi:10.1371/journal.pone.0072928.g005
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biphasic hHSC proliferation with concentrations as low as 10 pM
inducing significant increases in hHSC proliferation (Figure 8).
To investigate the role of the G-protein, PI3K, MEK, p38
MAPK and PKC intra-cellular signalling pathways on NE and
EPI-induced proliferation of hHSC, we now examined the effect
of their respective inhibitors at the concentrations shown: pertussis
toxin (PT, 100 ng/ml); wortmannin (WT, 100 nM); PD98059
(PD, 20nM); SB202190 (SB, 10 mM) and RO-320432 (RO, 1 mM)
as previously detailed [2,17]. Pertussis toxin pre-treatment
significantly reduced NE induced hHSC proliferation, while
pre-treatment with wortmannin, PD98059 and RO also slightly
but non-significantly reduced NE-induced proliferation. However,
pre-treatment with SB202190 markedly and significantly inhibited
NE-induced hHSC proliferation (Figure 9a). Therefore, the
proliferative effects of the predominant a1-adrenoceptor agonist
NE, on hHSC, are mediated by G-protein coupled adrenoceptors
with downstream effects mostly involving p38 MAPK. Conversely,
the proliferative effects of the predominant b-agonist EPI involves
G-protein coupled adrenoceptors mediated downstream by PI-3K
and MEK with minor contributions from p38 MAP and PKC,
Figure 6. Exogenous NE stimulates proliferation of hHSC. a) NE induced a dose-dependent, biphasic, enhancement of proliferation of hHSC,
with a maximal effect at 10 nM. Each bar represents mean 6 SEM of triplicate responses in one typical experiment, expressed as a percentage of the
response in serum free control wells. Similar results have been obtained on at least three other occasions; SF, serum free; * p,0.001, ** p,0.0001. b)
Phase contrast micrographs are shown as visual confirmation of actual cell number increase in the presence of increasing concentrations of NE.
doi:10.1371/journal.pone.0072928.g006
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since EPI effects were inhibited by PT and furthermore by WT
and PD (Figure 9b). The hHSC NPY receptors, as with the hHSC
adrenoceptors, appear also to be coupled to G-proteins with
downstream pathways involving PI-3K since PT and WT
inhibited NPY induced hHSC proliferation (Figure 10).
Lack of Endogenous NE increases apoptosis of hHSC
In the absence of serum (serum free, SF) (Figure 11a) as
expected, marked apoptosis was observed, which was reduced by
the presence of serum (Figure 11b), platelet derived growth factor,
PDGF (Figure 11c) or NE (Figure 11d). PRZ markedly induced
hHSC apoptosis to an even a greater extent than serum
deprivation (Figure 11e). The effect of PRZ was abrogated by
NE (Figure 11f). Therefore, hHSC endogenously produced NE
and exogenously applied NE appears to be a survival factor for
hHSC.
Exogenous NE induced collagen expression through
TGF-b
We now investigated whether NE applied to hHSC upregulated
collagen gene expression in tandem with increased proliferation.
NE significantly increased collagen-1a2 gene expression, at
concentrations upwards of 10 nM (Figure 12a). Additionally, NE
induced expression of TGF-b (Figure 12b), indicating that at least
some of the increased collagen expression could be mediated
through TGF-b.
Figure 7. Exogenous EPI stimulate proliferation of hHSC. a) EPI, as with NE, similarly induced proliferation of cultured activated hHSC, at EPI
concentrations of 1 nM–1 mM with a maximal effect at 10 nM. b) Prazosin (10 mM) significantly inhibited NE induced hHSC proliferation. PRL (10 mM)
also inhibited EPI induced hHSC proliferation. Results are expressed as a percentage of each agonist control (100%).
doi:10.1371/journal.pone.0072928.g007
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Pro-fibrotic effects of NE on hHSC are not mediated
through leptin, IL-4 or IL-13 and NE does not induce
production of IL-10
Besides TGF-b, leptin, IL-4 and IL-13 [25,26] are also involved
in hepatic fibrogenesis consequent to various aetiologies and IL-10
may be anti-fibrotic [25–28]. To determine if leptin, IL-4 or IL-13
are upregulated by NE in order to explain the pro-fibrotic effect of
NE, and whether there is simultaneous induction of IL-10 by NE,
we initially assayed by quantitative RT-PCR the expression of
these factors by hHSC cultured under conditions identical to those
used above to detect NE effects on hHSC proliferation. We found
no appreciable evidence of induction by NE of leptin, IL-4, IL-10
Figure 8. Exogenous NPY stimulate proliferation of hHSC. NPY induced proliferation of cultured activated hHSC, at concentrations as low as
10 pM. Results are expressed as a percentage of each agonist control (100%).
doi:10.1371/journal.pone.0072928.g008
Figure 9. Exogenous NE and EPI stimulate proliferation of hHSC
through p38 MAP, PI3K and MEK. a) Pre-treatment for 2 hours with
PT (G-protein inhibitor, 100 nM) and SB203580 (p38MAP inhibitor,
10 mM) significantly reduced NE induced hHSC proliferation, with WT
wortmannin (PI3K inhibitor, 100 nM), and PD98059 (MEK inhibitor,
100 nM) also slightly but non-significantly reducing NE-induced prolif-
eration. b) The proliferative effects of EPI were also inhibited by PT and
furthermore by WT, PD and RO (PKC inhibitor, 1 mM).
doi:10.1371/journal.pone.0072928.g009
Figure 10. Exogenous NPY stimulate proliferation of hHSC
through p38 MAP, PI3K and MEK. NPY proliferative effects on hHSC
were inhibited by PT and WT. Results (mean 6SEM of triplicate
responses in one typical experiment) are expressed as a percentage of
the response in serum free control wells. Similar results have been
obtained on at least three other occasions. SF, serum free; *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0072928.g010
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or IL-13 gene expression (results not shown). We also confirmed
by ELISA that there was no appreciable induction of leptin or IL-
13 protein (results not shown). Therefore, the pro-fibrotic effect of
NE on hHSC does not involve appear to involve leptin, IL-4 or IL-
13. These results are in keeping with our previous findings that in
Figure 11. Lack of Endogenous NE increases apoptosis of hHSC. Absence of serum induced marked apoptosis (a), reduced by presence of
serum (b), PDGF (c) or NE (d). PRZ markedly induced hHSC apoptosis more than serum deprivation (e), the effect of PRZ was abrogated by NE (f).
Results shown are from 1 typical experiment. Similar results have been obtained on at least 2 other occasions. PRZ significantly induced apoptosis
compared to serum alone or compared to NE alone (Serum alone 360.6% vs PRZ 1163%, p,0.05,n = 3; NE 460.2% vs PRZ 1163%, p,0.05,n = 3).
doi:10.1371/journal.pone.0072928.g011
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HSC from mice NE induced pro-fibrogenic without a requirement
for leptin [4].
Discussion
We have shown here that hHSC express adrenoceptors, which
are markedly upregulated in human livers with NAFLD cirrhosis.
Activated hHSC in culture express a1A, b1, b2 and b3
adrenoceptors, while no convincing expression of a1B or a1D
adrenoceptors was observed. This is to our knowledge the first
comprehensive report of the adrenoceptor profile of primary
hHSC including their expression of b3-adrenoceptors. hHSC also
robustly express Y1, Y4, and Y6 NPY receptors with little
expression of Y2 and Y5. These receptors are functional and are
possibly implicated in NAFLD fibrosis, since patients with F0
fibrosis had reduced expression of a1A, b1, b2 and b3
adrenoceptors or Y1, Y4 and Y6 NPY receptors, whereas patients
with NAFLD F4 fibrosis (cirrhosis) had exuberant expression of
a1A, b1, b2 and b3 adrenoceptors plus Y1, Y4 and Y6 NPY
receptors. These results suggest also that hHSC are potential
targets for the pathogenic effect of catecholamines in the liver,
consistent with recent data indicating that catecholamines
contribute to tissue repair and inflammation, in addition to
regulating vascular homeostasis [29]. Furthermore, hHSC express
functional dopamine-b-hydroxylase and synthesize/release the
cathecholamines NE plus EPI to regulate hHSC basal growth
since PRZ (a1-adrenoreceptor antagonist) and PRL (b-adreno-
ceptor antagonist) reduced hHSC basal growth. Endogenous NE is
also necessary for hHSC survival since there is markedly increased
hHSC apoptosis in the presence of PRZ. DBH expression was
markedly upregulated in livers with NAFLD cirrhosis.
NE is known to stimulate key intracellular kinases and signalling
pathways implicated in the hepatic fibrogenesis [add Ref 2, [3].
Here we found that exogenous NE, EPI and NPY also regulate
hHSC fibrogenic functions since NE, EPI and NPY dose-
dependently induced hHSC proliferation through G-protein
coupled receptors. The downstream effects of NE on hHSC are
shown here to be mediated by p38 MAP and that of EPI mediated
most likely by PI3K and MEK, with perhaps some minor
contribution from p38 MAP and PKC. The involvement of these
latter 2 pathways in hHSC proliferation needs clarifying in future
experiments. The intra-cellular pathways involved in the actions of
NE and EPI on hHSC as shown here, are similar to those reported
for their actions in murine HSC and other cell types [2,30].
Importantly, for our finding that the intra-cellular action of EPI on
hHSC probably involves MEK; the MEK inhibitor PD98059 has
recently been shown to reduce injury and fibrosis in a murine
model of lung fibrosis [31]. Additionally, the proliferative effects of
NPY on hHSC as shown here are similar to previous findings of
the effect of NPY on murine HSC [5], but the current findings are
to our knowledge the first comprehensive description of NPY
receptors on HSC and the signalling pathways therein.
NE and EPI induced hHSC proliferation were maximal at
10nM. NE induced hHSC proliferation is an a-adrenoceptor
mediated (PRZ inhibited) whilst EPI induced hHSC proliferation
is b-adrenoceptor mediated (PRL inhibited). NPY as with NE and
EPI dose-dependently induced hHSC proliferation with concen-
trations as low as 10 pM inducing significant increases in hHSC
proliferation. Exogenously administered NE and EPI, moreover,
induced collagen expression through TGF-b because NE and EPI
applied to hHSC upregulated collagen gene expression in tandem
with increased proliferation. Therefore, at least some of the
increased collagen expression induced by NE and EPI in hHSC is
mediated through TGF-b, in line with our previous study in mice
[2]. It has been shown previously that HSC secrete pro-
inflammatory chemokines such as interleukins [32,33] and
inflammatory mediators derived from lymphocytes can stimulate
HSC fibrogenic potential [33], such that chemokine secretion by
NE might enhance inflammation in chronic liver disease. In our
study however, we did not find appreciable evidence of induction
by NE of leptin, IL-4, IL-10 or IL-13. In support of our findings
here, a study using a Mdr2(2/2) mouse model, displaying
blockade of b-adrenoceptors has been shown to be a promising
therapeutic strategy in the treatment of human primary sclerosing
cholangitis [34]. Moreover, b-adrenoceptors mediate liver NE
modulation of pro-inflammatory responses, cardiac dysfunction
and portal hypertension in cirrhotic patients and rodent models of
the disease [35–39]. In summary, our study clearly shows that
hHSC express adrenergic and NPY receptors which are
upregulated in vivo with fibrosis. Additionally, hHSC synthesise
and require the cathecholamines NE and EPI for optimal survival
and NE, EPI and NPY stimulate the proliferation of hHSC with
NE also shown to induce collagen gene expression in cultured
hHSC. These findings suggest therefore that adrenergic and NPY
antagonists may be novel anti-fibrotic agents in NAFLD.
Figure 12. Exogenous NE induced collagen expression through
TGF-b. a) NE upwards of 10nM significantly increased hHSC collagen-
1a2 gene expression, with absence of serum and TGF-b as negative and
positive controls. b) NE significantly induced expression TGF-b. Results
(mean 6SEM of triplicate responses in one typical experiment) are
expressed as a percentage of the response in serum free control wells,
vs SF, *p,0.05. Similar results have been obtained on at least three
other occasions.
doi:10.1371/journal.pone.0072928.g012
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